JPS55167221A - Anticancer drug - Google Patents

Anticancer drug

Info

Publication number
JPS55167221A
JPS55167221A JP7493879A JP7493879A JPS55167221A JP S55167221 A JPS55167221 A JP S55167221A JP 7493879 A JP7493879 A JP 7493879A JP 7493879 A JP7493879 A JP 7493879A JP S55167221 A JPS55167221 A JP S55167221A
Authority
JP
Japan
Prior art keywords
formula
anticancer drug
activity
organs
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP7493879A
Other languages
Japanese (ja)
Inventor
Susumu Tsuboi
Shigeyuki Yasuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP7493879A priority Critical patent/JPS55167221A/en
Publication of JPS55167221A publication Critical patent/JPS55167221A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE: An anticancer drug having activity against almost all cancers, comprising maleic hydragide as an active constituent.
CONSTITUTION: An anticancer drug comprising as an active constituent maleic hydrazide (1,2-dihydropyridazine-3,6-dione) of formula I which is obtained as a ketoenol tautomer with 3,6-dihydroxypyridazine of formula II by reacting maleic anhydride with hydrazine. Although known to have a growth-regulating activity on the juvenile cells of plants, the compound of formula I was found to have not only low toxicity snd little side effects but also the anticancer activity or human bodies by being administered orally or parenterally particularly with the efficacy of 57% against the cancers in digestive organs, genital organs, respiratory organs, etc.
COPYRIGHT: (C)1980,JPO&Japio
JP7493879A 1979-06-13 1979-06-13 Anticancer drug Pending JPS55167221A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP7493879A JPS55167221A (en) 1979-06-13 1979-06-13 Anticancer drug

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7493879A JPS55167221A (en) 1979-06-13 1979-06-13 Anticancer drug

Publications (1)

Publication Number Publication Date
JPS55167221A true JPS55167221A (en) 1980-12-26

Family

ID=13561782

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7493879A Pending JPS55167221A (en) 1979-06-13 1979-06-13 Anticancer drug

Country Status (1)

Country Link
JP (1) JPS55167221A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0665223A1 (en) * 1994-01-28 1995-08-02 Takeda Chemical Industries, Ltd. Antitumor agent, novel 3(2H)-pyridazinone derivatives and their preparation
JP2011121984A (en) * 2003-11-19 2011-06-23 Array Biopharma Inc Bicyclic inhibitor of mek and method of use thereof
KR101336692B1 (en) * 2011-12-27 2013-12-03 경희대학교 산학협력단 Poly(ethylene oxide)-based block copolymer bearing hydrazide moiety and iron oxide nanoparticle stabilized by the same

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0665223A1 (en) * 1994-01-28 1995-08-02 Takeda Chemical Industries, Ltd. Antitumor agent, novel 3(2H)-pyridazinone derivatives and their preparation
JP2011121984A (en) * 2003-11-19 2011-06-23 Array Biopharma Inc Bicyclic inhibitor of mek and method of use thereof
KR101336692B1 (en) * 2011-12-27 2013-12-03 경희대학교 산학협력단 Poly(ethylene oxide)-based block copolymer bearing hydrazide moiety and iron oxide nanoparticle stabilized by the same

Similar Documents

Publication Publication Date Title
ES473451A1 (en) Imidazole derivatives their synthesis and their pharmaceutical formulations.
CA2040982A1 (en) N-(3-fluoro-2-phosphonylmethoxypropyl) derivatives of purine and pyrimidine heterocyclic bases, their preparation and use
FR2363329A1 (en) 4-Carbamoyl-5-hydroxy-imidazole - used to treat cancer, nephritis and rheumatism
JPS55167221A (en) Anticancer drug
IE780981L (en) 6-(substituted amino)-penam compounds
ES482742A1 (en) Substituted 2-phenylamino-imidazolines-(2), their acid addition salts, medicaments containing them and processes for their preparation.
ES455721A1 (en) Urapidil/furosemide compounds, compositions and use
JPS57114512A (en) Antidia beticagent comprising (3-dimethyl-carbamoxy- phenyl)trimethyl ammonium derivative
JPS54151134A (en) Antitumorigenic agent
JPS5536454A (en) Novel immunosuppressive agent
IE43863L (en) Imidazole derivatives
ES471874A1 (en) Herbicidally active 1,2,4-triazin-5-one derivatives
JPS5610114A (en) Novel analgesic and anti-inflammatory agent
JPS5278887A (en) Synthesis of n-(2-tetrahydrofuryl)-5-fluorouracil
JPS5248677A (en) Preparation of pyrimidine derivatives
JPS57165318A (en) Remedy for asthma
JPS5289680A (en) Preparation of 1-(2-tetrahydrofuryl)-5-flurouracil
Osswald et al. Potentiation of the chemotherapeutic action of Bleomycin by combination with inosine on HRS-Sarcoma
JPS5268182A (en) Preparation of novel triazole derivatives
JPS53108987A (en) Preparation of 1-(2'-tetrahydrofuryl)-5-fluorouracil
JPS5325534A (en) Mandelic acid glucosides and their anti-cancerous preparations
JPS5718616A (en) Remedy for nephropathy
JPS525782A (en) Preparation of 1-phthalazinone
JPS57171989A (en) Aminometyl-secalonic acid and its preparation
FR2424270A1 (en) 4,5-Di:hydro-2-imidazolyl-amino-isoquinoline derivs. - useful as antihypertensives having low toxicity and free from sedative side effects